Provided by Tiger Trade Technology Pte. Ltd.

AKESO

89.900
-5.450-5.72%
Volume:14.10M
Turnover:1.28B
Market Cap:82.80B
PE:-62.49
High:93.700
Open:93.600
Low:89.600
Close:95.350
52wk High:159.800
52wk Low:80.200
Shares:921.00M
HK Float Shares:921.00M
Volume Ratio:0.98
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.439
ROE:-13.59%
ROA:-4.57%
PB:8.36
PE(LYR):-62.49
PS:20.56

Loading ...

Movement Alert|Akeso Rises 11.77% in Regular Trading, ASCO Plenary Session Data Shows Ivonescimab Beats PD-1 Combo in Overall Survival

Market Focus
·
Jun 01

AKESO Shares Surge on Positive Phase III Lung Cancer Trial Data

Stock News
·
Jun 01

AKESO Unveils Over 40 Clinical Trial Findings for Innovative Drugs at 2026 ASCO

Stock News
·
Jun 01

Akeso says Phase III HARMONi-6 trial shows ivonescimab-chemo cuts death risk 34% in first-line sq-NSCLC

Reuters
·
May 31

Harmoni-6 Demonstrates Significant Overall Survival Benefit (Hr=0.66): Ivonescimab Plus Chemotherapy Superior to Pd-1 Plus Chemotherapy in First-Line Sq-Nsclc Landmark Results to Be Presented at Asco 2026 Plenary Session

THOMSON REUTERS
·
May 31

CORRECTED-Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial (May 31)

Reuters
·
May 31

Stock Track | AKESO Soars 5.07% Intraday as Ivonescimab Data Selected for ASCO Plenary Presentation

Stock Track
·
May 29

Movement Alert|Akeso Bio Rises 3.99% in Regular Trading, ASCO Plenary Session Oral Presentation of Ivonescimab OS Data Set to Unveil

Market Focus
·
May 29

Stock Track | AKESO Plummets 5.03% Intraday on Disappointing Ivonescimab Phase III Interim Results

Stock Track
·
May 28

Hong Kong Stock Connect Biotech Sector Extends Over 8-Month Slump, Key ETF Hits Record Low

Deep News
·
May 28

Movement Alert|Akeso Bio Falls 3.13% in Regular Trading, Ivonescimab Global Phase III Interim Analysis Missing Endpoint Continues to Weigh on Valuation

Market Focus
·
May 28

Movement Alert|Akeso Inc Rises 3.03% in Regular Trading, ASCO Plenary Session Oral Presentation Approaching as Key Catalyst

Market Focus
·
May 27

Akeso says Phase 3 HARMONi-6 overall survival data for ivonescimab in first-line squamous NSCLC lands ASCO plenary slot

Reuters
·
May 26

BUZZ-J&T Global Express leads gain in newcomers to Hang Seng Index

Reuters
·
May 26

Movement Alert|Akeso Bio Falls 3.09% in Regular Trading, Ivonescimab Global Phase III Interim Miss Continues to Weigh on Valuation

Market Focus
·
May 26

Hang Seng Index Quarterly Review Boosts Industrial and Healthcare Sector Coverage; Six Stocks May Enter Southbound Trading

Stock News
·
May 25

Hang Seng Index Quarterly Review Results Announced: New Additions Include J&T Express, BeiGene, and CHALCO

Deep News
·
May 22

Zhipu and MiniMax Poised for Inclusion in Hang Seng Tech Index

Deep News
·
May 22

A Look At Akeso (SEHK:9926) Valuation After New Cadonilimab Approval In Colorectal Cancer

Simply Wall St.
·
May 22

Stock Track | AKESO Plummets 5.08% Intraday on Disappointing Ivonescimab Phase III Trial Results

Stock Track
·
May 22